122 related articles for article (PubMed ID: 20529806)
1. Standards for the treatment of relapsed chronic lymphocytic leukemia: a case-based study.
Kater AP; Tonino SH
Clin Lymphoma Myeloma Leuk; 2010 Jun; 10 Suppl 1():S34-41. PubMed ID: 20529806
[TBL] [Abstract][Full Text] [Related]
2. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
Robak T
Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872
[TBL] [Abstract][Full Text] [Related]
3. Novel immune-based treatment strategies for chronic lymphocytic leukemia.
Wierda WG; Kipps TJ; Keating MJ
J Clin Oncol; 2005 Sep; 23(26):6325-32. PubMed ID: 16155015
[TBL] [Abstract][Full Text] [Related]
4. Treatment options for newly diagnosed patients with chronic lymphocytic leukemia.
Erba HP
Curr Hematol Rep; 2004 Jan; 3(1):47-53. PubMed ID: 14695850
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial.
Elter T; Borchmann P; Schulz H; Reiser M; Trelle S; Schnell R; Jensen M; Staib P; Schinköthe T; Stützer H; Rech J; Gramatzki M; Aulitzky W; Hasan I; Josting A; Hallek M; Engert A
J Clin Oncol; 2005 Oct; 23(28):7024-31. PubMed ID: 16145065
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Vazquez ER; Spigel DR; Raefsky E; Bearden JD; Saez RA; Greco FA
Cancer; 2008 Mar; 112(6):1288-95. PubMed ID: 18189296
[TBL] [Abstract][Full Text] [Related]
7. Alemtuzumab in chronic lymphocytic leukemia.
James DF; Kipps TJ
Future Oncol; 2007 Feb; 3(1):29-42. PubMed ID: 17280499
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53.
Osuji NC; Del Giudice I; Matutes E; Wotherspoon AC; Dearden C; Catovsky D
Haematologica; 2005 Oct; 90(10):1435-6. PubMed ID: 16219582
[TBL] [Abstract][Full Text] [Related]
9. Antibody therapy for chronic lymphocytic leukemia: a promising new modality.
Lin TS; Moran M; Lucas M; Waymer S; Jefferson S; Fischer DB; Grever MR; Byrd JC
Hematol Oncol Clin North Am; 2004 Aug; 18(4):895-913, ix-x. PubMed ID: 15325705
[TBL] [Abstract][Full Text] [Related]
10. Chronic lymphocytic leukemia: current and emerging treatment approaches.
Kay NE; Rai KR; O'Brien S
Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 22):1-10; quiz 11-2. PubMed ID: 17143256
[TBL] [Abstract][Full Text] [Related]
11. Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era.
Nabhan C; Gartenhaus RB; Tallman MS
Leuk Res; 2004 May; 28(5):429-42. PubMed ID: 15068894
[TBL] [Abstract][Full Text] [Related]
12. Chemoimmunotherapy of chronic lymphocytic leukemia.
Tam CS; Keating MJ
Best Pract Res Clin Haematol; 2007 Sep; 20(3):479-98. PubMed ID: 17707835
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab in the treatment of chronic lymphocytic lymphoma.
Boyd K; Dearden CE
Expert Rev Anticancer Ther; 2008 Apr; 8(4):525-33. PubMed ID: 18402519
[TBL] [Abstract][Full Text] [Related]
14. Advances in the diagnosis and treatment of chronic lymphocytic leukemia.
Abbott BL
Clin Adv Hematol Oncol; 2004 Jul; 2(7):448-54. PubMed ID: 16163221
[TBL] [Abstract][Full Text] [Related]
15. Novel therapeutic strategies with alemtuzumab for chronic lymphocytic leukemia.
Rai KR
Semin Oncol; 2006 Apr; 33(2 Suppl 5):S15-22. PubMed ID: 16720199
[TBL] [Abstract][Full Text] [Related]
16. The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia.
Visco C; Finotto S; Pomponi F; Sartori R; Laveder F; Trentin L; Paolini R; Di Bona E; Ruggeri M; Rodeghiero F
Am J Hematol; 2013 Apr; 88(4):289-93. PubMed ID: 23450436
[TBL] [Abstract][Full Text] [Related]
17. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.
Moreton P; Kennedy B; Lucas G; Leach M; Rassam SM; Haynes A; Tighe J; Oscier D; Fegan C; Rawstron A; Hillmen P
J Clin Oncol; 2005 May; 23(13):2971-9. PubMed ID: 15738539
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibody combinations in CLL: evolving strategies.
Faderl S; O'Brien S; Keating MJ
Best Pract Res Clin Haematol; 2006; 19(4):781-93. PubMed ID: 16997183
[TBL] [Abstract][Full Text] [Related]
19. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria.
Fiegl M; Falkner A; Hopfinger G; Brugger S; Zabernigg A; Bauer F; Haslbauer F; Demirtas D; Grossschmidt P; Tatzreiter G; Gastl G; Greil R;
Cancer; 2006 Nov; 107(10):2408-16. PubMed ID: 17054106
[TBL] [Abstract][Full Text] [Related]
20. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
